Debt-free Balance SheetA zero-debt balance sheet reduces refinancing and interest-rate risk and preserves financial flexibility. For a discovery-focused biotech this durable capital structure supports licensing negotiations, funds selective R&D or partnering activities, and improves resilience across typical biotech cycles.

Profitability Inflection And Material Revenue GrowthA sustained move to positive net income and material revenue improvement signals successful de-risking of programs or milestone monetization. This strengthens internal funding capacity, enhances partner credibility, and creates a more durable operating base for advancing or licensing additional projects.

Lean, Focused OrganizationA small, specialized team supports low fixed overhead and operational agility in early-stage drug discovery. This structure lowers cash burn, allows flexible resource allocation to priority projects, and makes the company an efficient partner for alliance-driven development models over the medium term.

Bears Say

Lumpy Cash FlowsReliance on milestone and licensing receipts produces volatile cash inflows that complicate forecasting and operating planning. Over a 2–6 month horizon, this structural lumpiness can force timing-sensitive funding or pause discretionary R&D until partner triggers occur or cash is available.

Revenue Reliant On Partner Deals And MilestonesA business model dependent on external licensing means commercial outcomes hinge on partner decisions, clinical progress and regulatory events. That structural dependency concentrates execution risk off the company's balance sheet and can delay or reduce revenue realization despite internal scientific progress.

Historical Equity Instability And Prior LossesPast low equity and recurring losses through 2020–2024 show the company has been funding-sensitive and volatile. Even with recent profits, this history implies potential for future dilution or funding needs if milestone timing slips, reducing predictability and partner/investor confidence.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was kr0.36 and its highest was kr2.35 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is kr196.26M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 69 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported kr1.073 earnings per share for the quarter, beating the consensus estimate of N/A by kr1.073.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of kr1.073 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in SE:SPRINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.